Calidi Biotherapeutics, Inc.
CLDI
$0.415
-$0.016-3.71%
AMEX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 50.21% | -149.70% | 53.87% | -11.81% | -6.10% |
| Total Depreciation and Amortization | 7.97% | 13.04% | 3.85% | 104.37% | 308.99% |
| Total Amortization of Deferred Charges | 101.43% | -95.52% | -94.82% | -92.04% | -334.45% |
| Total Other Non-Cash Items | 1,856.67% | 107.95% | -91.36% | -63.29% | -100.75% |
| Change in Net Operating Assets | -175.30% | 92.92% | 17.16% | 19,070.00% | 1,066.99% |
| Cash from Operations | -4.57% | 63.41% | -6.21% | -23.30% | -33.80% |
| Capital Expenditure | 92.86% | 91.67% | 100.00% | 96.35% | 56.52% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 85.71% | 90.48% | 100.00% | 96.35% | 78.26% |
| Total Debt Issued | -- | -- | -100.00% | 36.17% | -100.00% |
| Total Debt Repaid | 99.17% | -5.88% | -10,617.65% | -21.05% | -9,891.30% |
| Issuance of Common Stock | -- | 7,370.00% | 10,916.00% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 23.94% | -23.36% | 207.72% | -112.82% | -123.22% |
| Cash from Financing | 543.07% | -72.06% | -20.91% | -20.52% | -168.49% |
| Foreign Exchange rate Adjustments | 184.21% | -243.48% | -30.00% | -- | -337.50% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 193.85% | -86.87% | -126.72% | -247.35% | -2,926.90% |